Sol-Gel Technologies (SLGL) Total Current Liabilities (2016 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Total Current Liabilities of $6.3 million for Q1 2026, up 38.05% year-over-year from $4.6 million in Q1 2025, and up 2.3% quarter-over-quarter from $6.2 million in Q4 2025.
Sol-Gel Technologies (SLGL) Total Current Liabilities (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Total Current Liabilities for 11 consecutive years, with $6.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 38.05% year-over-year to $6.3 million; the TTM figure through Mar 2026 stood at $6.3 million (up 38.05% YoY), while the FY2025 annual figure was $6.2 million, up 16.76% from the prior year.
- Total Current Liabilities climbed to $6.3 million in Q1 2026 per SLGL's latest filing, from $6.2 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $6.5 million in Q3 2024 and bottomed at $2.6 million in Q3 2022.
- Historically, Total Current Liabilities has averaged $4.8 million across 5 years, with a median of $5.0 million in 2025.
- Annual changes were most pronounced in 2022 — Total Current Liabilities sank 72.74% — and 2023, when it soared 75.72%.
- Sol-Gel Technologies' Total Current Liabilities stood at $3.3 million in 2022, then surged by 35.84% to $4.5 million in 2023, then gained by 16.87% to $5.3 million in 2024, then grew by 16.76% to $6.2 million in 2025, then gained by 2.3% to $6.3 million in 2026.
- Business Quant data shows SLGL's Total Current Liabilities at $6.3 million in Q1 2026, $6.2 million in Q4 2025, and $6.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - | 6.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.31 Mn |
| Dec 31, 2025 | 6.17 Mn |
| Sep 30, 2025 | 6.15 Mn |
| Jun 30, 2025 | 4.96 Mn |
| Mar 31, 2025 | 4.57 Mn |
| Dec 31, 2024 | 5.29 Mn |
| Sep 30, 2024 | 6.53 Mn |
| Jun 30, 2024 | 5.20 Mn |
| Mar 31, 2024 | 5.23 Mn |
| Dec 31, 2023 | 4.52 Mn |
| Sep 30, 2023 | 4.51 Mn |
| Jun 30, 2023 | 5.67 Mn |
| Mar 31, 2023 | 3.92 Mn |
| Dec 31, 2022 | 3.33 Mn |
| Sep 30, 2022 | 2.60 Mn |
| Jun 30, 2022 | 3.23 Mn |
| Mar 31, 2022 | 4.21 Mn |
| Dec 31, 2021 | 11.69 Mn |
| Sep 30, 2021 | 9.53 Mn |
| Jun 30, 2021 | 5.16 Mn |